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Abstract
Background/Aims: Essential to bringing innovative cancer treatments to patients is voluntary participation in clinical
trials but approximately 8% of American cancer patients are enrolled onto a trial. We used a domain-oriented frame-
work to assess barriers to cancer clinical trial enrollment.
Methods: Physicians (MD, DO, fellows, residents) and research staff (physician assistants, nurse practitioners, staff and
research nurses, clinical assistants, and program coordinators) involved in clinical research at a comprehensive cancer
center completed an online survey in 2017; adult cancer patients not currently enrolled in a trial were interviewed in
2018. To inform the construct of our physician/staff and patient surveys and to assess barriers to clinical trial enrollment,
we first conducted in-depth interviews among 14 key informants representing medical, hematologic, gynecologic, neuro-
logic, radiation oncology, as well as members of the clinical research team (one clinical research coordinator, one
research nurse practitioner). Perceived structural, provider- and patient-level barriers to clinical trial enrollment were
assessed. Differences in perceptions, attitudes, and beliefs toward clinical trial enrollment between (1) physicians and
staff, (2) patients by ethnicity, and (3) physicians/staff and patients were examined.
Results: In total, 120 physicians/staff involved in clinical research (39.2% physicians, 60.8% staff; 48.0% overall response
rate) and 150 cancer patients completed surveys. Nearly three-quarters of physician/staff respondents reported difficulty
in keeping track of the eligibility criteria for open studies but was more often cited by physicians than staff (84.4% vs
64.3%, p = 0.02). Physicians more often reported lack of time to present clinical trial information than did staff
(p \ 0.001); 44.0% of staff versus 18.2% of physicians reported patient family interaction as a clinical trial enrollment
barrier (p = 0.007). Hispanic patients more often stated they would join a trial, even if standard therapy was an option
compared to non-Hispanic patients (47.7% vs 20.8%, p = 0.002). Comparing the beliefs and perceptions of physicians/
staff to those of patients, patients more often reported negative beliefs about clinical trial enrollment (e.g. being in a trial
does not help patients personally, 32.9% vs 1.8%, p \ 0.001) but less often felt they had no other options when agreeing
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to join (38.1% vs 85.6%, p \ 0.001), and less often refused clinical trial enrollment due to lack of understanding (9.1% vs
63.3%, p = 0.001) than reported by physicians/staff.
Conclusion: Our findings indicate a wide gap between physician/staff and patient attitudes and beliefs about clinical trial
enrollment and highlight the importance of focusing future initiatives to raise awareness of this incongruency. Reconciling
these differences will require tailored education to reduce implicit biases and dispel misperceptions. Strategies to
improve the quality of patient–provider communication and address infrastructure and resource issues are also needed
to improve patient enrollment onto cancer clinical trials.
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Background
Cancer clinical trials are a crucial step in advancing can-
cer treatment, and greater participation in clinical trials
expedites these advances with potential to improve the
lives of people with cancer. Most cancer patients, how-
ever, do not participate in a clinical trial. Recent esti-
mates put overall clinical trial enrollment (CTE) in the
United States at 8%, ranging from 6.3% to 7.0% at
community centers and 14.0% to 15.9% at academic
centers.1–3 Although higher than the often cited partici-
pation rates of 3%–5%,4–7 participation in clinical trials
has changed little over the past few decades.
Barriers to cancer trial enrollment are complex and
multifaceted. Several models to understand and address
low clinical trial participation have been described, and
all propose that barriers at multiple levels affect the
phenomenon, specifically at the system, provider, and
patient levels,1,3 as well as the interaction between each
of these levels.8,9 Unger et al. proposed that CTE bar-
riers can be categorized as structural (e.g. trial avail-
ability), clinical (e.g. patient eligibility), and attitudinal
factors (both physician and patient). To address the
structural barrier of trial availability, the National
Cancer Institute funds cooperative groups to develop
trials that are then available across the country through
mechanisms that include the National Cancer Institute
(NCI)-Community Oncology Research Program
(NCORP).10 Exclusion of potentially eligible cancer
patients due to rigid eligibility criteria,11,12 particularly
individuals from underrepresented age, gender, and
racial/ethnic groups for many clinical trials where rep-
resentation is disproportionately low,13 is an issue that
is currently under evaluation by the American Society
of Clinical Oncology.14 For example, ethnic and racial
minorities make up 38.7% of the US population15 but
only make up 2%–16% of those enrolled in American
cancer clinical trials,13,15,16 with 0.1% are American
Indian, 2.2% Hispanic, 3.3% Asian, and 6.1% Black/
African American.17 This, however, conflicts with
reports indicating that racial and ethnic minority
patients are as willing as whites to participate in health
research and clinical trials.18,19 Much research has
focused on addressing patient-related barriers as
ultimately patients make the final decision whether or
not to participate in a clinical trial.2,9,20,21 Interventions
targeted toward patients alone, however, have variable
effect; flexible and multifaceted strategies that address
both patients and providers were found to be more
effective.22
Although, substantial work has been done to under-
stand barriers to clinical trial participation, few studies
have specifically targeted minority participation using a
domain-oriented framework that includes an evalua-
tion of provider and patient attitudes. Minorities repre-
sent 33% of all cancer patients seeking care at our
large, urban NCI-Comprehensive Cancer Center and
Minority Underserved NCI-Community Oncology
Research Program (MU-NCORP) site,23 21% of whom
are Hispanic. However, the proportion of Hispanics in
our catchment area is even higher at 27.4%, ranging
from 17.0% in Rockland County to 55.4% in the
Bronx, New York. Our most recent efforts to increase
minority CTE based on the Accrual to Clinical Trial
framework24 included hiring a bilingual clinical trials
navigator and conducting awareness campaigns to edu-
cate providers and patients. These efforts are expected
to increase accrual to clinical trials, specifically among
minority patients; however, minority CTE continues to
be a challenge.
To identify actionable factors to increase CTE
among of minority patients in general and Hispanic
patients specifically, we examined the structural, and
physician, and patient attitudinal barriers to cancer
clinical trial participation among the providers and
diverse groups of patients with cancer at our site. We
also evaluated the knowledge and attitudes about clini-
cal trials as well as perceptions about the barriers to
CTE among key clinical personnel engaged in the con-
duct of cancer clinical trials and among a racially/ethni-
cally diverse cancer patient population.
Methods
Setting and subjects
All procedures were conducted at a large urban
Minority-Underserved NCORP site Columbia
Hillyer et al. 185
University Irving Medical Center (CUIMC). Physicians
involved in clinical research and trial staff were identi-
fied from Cancer Center membership rosters. Cancer
patient participants were recruited at medical, gyneco-
logic, neurologic, and hematologic oncology clinics.
Included were patients who were under the care of a
cancer center clinical oncologist and were not currently
enrolled in a clinical trial. Those not yet diagnosed with
cancer or who were seeking second opinions regarding
diagnosis were excluded. Participants were interviewed
in the language of their preference (English or Spanish)
by bilingual research team members. All procedures
were approved by the CUIMC Institutional Review
Board.
Development of physician, staff, and patient surveys
To inform the construct of our physician/staff and
patient surveys and to assess barriers to CTE, we first
conducted in-depth interviews among 14 key infor-
mants representing medical, hematologic, gynecologic,
neurologic, radiation oncology, as well as members of
the clinical research team (one clinical research coordi-
nator, one research nurse practitioner). Key informants
provided insight to successful strategies to increase
accrual such as methods to identify potential partici-
pants, the importance of bilingual staff, and the devel-
opment of a pervasive trials-friendly culture. Barriers
identified included space and time constraints; need for
increased coordinator support; desire for certain
disease-specific trials; and perceived poor communica-
tion between oncology groups and subspecialties.
Physicians and staff survey procedures
The physician and staff surveys were conducted August
through September 2017. An email invitation addressed
from the Chief of the division of hematology/oncology
(GS) was distributed to 250 physicians (MD, DO, fel-
lows, and residents), clinical and research staff (physi-
cian assistants, nurse practitioners, staff and research
nurses, clinical assistants, and program coordinators).
A brief introduction to the study was included along
with a unique link to a web-based informed consent
and survey in Qualtrics. Consent and survey responses
were uploaded via a secure Internet connection.
Reminders were sent twice at 1-week intervals for non-
respondents.
The survey was developed based on a review of the
literature and the key informant interviews. Prior to
implementation, the feasibility of survey administration
was tested among a sample of research coordinators
and was found to be acceptable. The survey took
approximately 8 min to complete. Structural barriers
encountered in cancer CTE25 and personal positive and
negative attitudes toward clinical trials25–27 were
assessed. Perceived reasons why, from the participant’s
(clinical researcher/staff) perspective, cancer patients
enroll in clinical trials28 and decline participation were
determined.25–27 Reasons for study refusal were
grouped as patient-related, psychosocial, logistic, and
trial-related factors, and financial concerns based on
categories identified in the literature.
Patient survey procedures
We used a convenience sampling strategy to approach
adult cancer patients, aged 18 years and older in oncol-
ogy clinic waiting rooms over a 6-month period.
Patients who were under the care of a physician from
the institution and who were not currently participating
in a clinical trial were considered eligible to participate
in this study. Surveys were conducted in the language
preferred by the participant (English or Spanish) in a
private area or examination room by bilingual research
team members. Language in which the survey was con-
ducted was recorded. Demographic information includ-
ing age, gender, race/ethnicity, educational level, and
marital status was collected. Health literacy was deter-
mined using a brief literacy screener,29 and awareness
of clinical trials was evaluated by asking a single ques-
tion, ‘‘Do you know what a clinical trial is?’’ with
responses recorded as ‘‘Yes/No.’’ Patient participants
were asked if a clinical trial was ever offered to them
and, if so, did they participate along with reasons for
joining28 or declining.25–27 These questions, as well as
questions regarding personal attitudes and beliefs
toward clinical trials, mirrored questions asked of the
physicians and staff. Finally, a series of five questions
to ascertain the circumstances under which a patient
would consider joining a clinical trial were posed to
patient participants (e.g. ‘‘If you had tried all available
standard treatment but it did not work, would you con-
sider participating in a clinical trial for a new
treatment?’’).
Data analysis
Descriptive analyses include frequency distributions,
and mean, standard deviation, median, and range for
continuous variables. Univariable tests of association
using the chi-square test were performed to assess dif-
ferences in categorical type questions and Student’s t
test for continuous variables between physicians and
clinical research staff and between Hispanic and non-
Hispanic cancer patients. Comparison between positive
and negative clinical trial attitudes, and reasons for clin-
ical trial participation and declination as perceived by
physicians/staff versus cancer patients was conducted
using chi-square test. P values \0.05 were considered
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statistically significant, and all analyses were performed
using IBM SPSS (version 24).30 All procedures were
reviewed and approved by the Columbia University
Medical Center Institutional Review Board.
Results
Surveys were distributed to 115 physicians and 135 clin-
ical/research staff involved in the conduct of clinical
trials. Of these, 161 responses were received (response
rate = 64.4%; 79/115 = 68.7% physicians and 82/
135 = 60.7% clinical/research staff). Duplicates and
surveys with ø50% missing data were removed, result-
ing in 120 surveys for analysis; 47 physicians (39.2%)
and 73 (60.8%) clinical/research staff. A total of 150
cancer patients completed interviews; 98 (65.3%) were
non-Hispanic and 44 Hispanic (29.3%).
Physician and staff responses
Nearly three-quarters (n = 74, 73.3%) of respondents
reported difficulty in keeping track of the eligibility cri-
teria for open studies (Table 1). This was more often
cited by physicians than staff (84.4% vs 64.3%,
p = 0.02). Other barriers included complicated paper-
work (n = 55, 54.5%), difficulty in communicating
complex information to patients (n = 56, 57.1%), and
patients refusing placebo (n = 43, 51.8%). While over-
all only 31.9% of respondents found interacting with
the patient’s family to be a barrier to enrollment, staff
twice as often as physicians (44.0% vs 18.2%,
p = 0.007) reported this barrier. Conversely, physi-
cians twice as often as research staff found making time
to discuss clinical trials with patients during office visits
to be difficult (67.4% vs 34.0%, p = 0.001).
Patient responses
The majority of cancer patient surveys were conducted
in English (78.0%); most participants were female
(59.3%), White (61.3%), and non-Hispanic (70.7%)
(Table 2). Approximately one-quarter did not know
what a clinical trial is, and only 21.3% had ever been
invited to participate in a trial; of those, 66% joined the
trial (14.0% of all participants). When asked about cir-
cumstances under which they would ‘‘definitely’’ partic-
ipate in a clinical trial, only 24% stated that would join
today if asked. The highest proportion of participants
(72.7%) would ‘‘definitely’’ consider a clinical trial if
they thought their cancer was incurable and the clinical
trial offered a new treatment, followed by 66.0% who
would ‘‘definitely’’ consider a trial of a new treatment if
all available treatment had failed.
Hispanics were more likely to state that they did not
know what a clinical trial is compared with non-
Hispanic patients (52.3% vs 16.0%, p \ 0.001), but
were as likely as non-Hispanics to report being invited
to participate in a clinical trial (11.4% vs 25.5%,
Table 1. Structural barriers encountered by physicians and staff enrolling cancer patients onto clinical trials (N = 120), September–
November 2017.
Total, N = 120 Physicians, n = 47 Staff n = 73 P value
n (%) n (%) n (%)
Administrative
Paperwork is very complicated 55 (54.5) 26 (57.8) 29 (51.5) 0.55
Lack of support staff to assist with enrollment 47 (45.6) 24 (52.2) 23 (40.4) 0.23
Enrollment process is too time consuming 48 (49.0) 26 (56.5) 22 (42.3) 0.16
Difficult to keep track of the eligibility criteria 74 (73.3) 38 (84.4) 36 (64.3) 0.02
Patient-related
Patients frequently miss scheduled appointments 35 (35.7) 14 (32.6) 21 (38.2) 0.56
Patients refuse placebo 43 (51.8) 20 (50.0) 23 (53.5) 0.75
Interacting with the patient’s family 30 (31.9) 8 (18.2) 22 (44.0) 0.007
Minority patients are difficult to enroll 28 (30.8) 12 (28.6) 16 (32.7) 0.67
Process-related
Very few eligible patients 45 (46.9) 22 (51.2) 23 (43.4) 0.45
Clinical trial protocols are too rigid 36 (35.0) 16 (34.8) 20 (35.1) 0.97
Too difficult to match patients to trials 24 (28.2) 13 (31.7) 11 (25.0) 0.49
Lack of minority physicians to recruit
minority patients
40 (43.0) 20 (45.5) 20 (40.8) 0.65
Making time to discuss clinical trials with patients
during office visits
47 (50.5) 31 (67.4) 16 (34.0) 0.001
Translating documents into Spanish and other languages
is difficult and expensive
42 (44.7) 21 (48.8) 21 (41.2) 0.46
Communicating complex information to patients
is very difficult
56 (57.1) 26 (56.5) 30 (57.7) 0.91
No space to enroll and consent patients 30 (30.6) 13 (28.3) 17 (32.7) 0.63
Heavy clinical patient volume 32 (35.6) 20 (44.4) 12 (26.7) 0.08
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Table 2. Cancer patient clinical trials knowledge, attitudes, and beliefs by ethnicity (N = 150), May–September 2018.
Total (N = 150) Non-Hispanic (n = 106) Hispanic (n = 44) p
n (%) n (%) n (%)
Survey language \0.001
English 117 (78.0) 104 (98.1) 13 (29.5)
Spanish 33 (22.0) 2 (1.9) 31 (70.5)
Demographics
Gender 0.97
Male 61 (40.7) 43 (40.6) 18 (40.9)
Female 89 (59.3) 63 (59.4) 26 (59.1)
Age
Mean (SD) 61.5 (14.1) 61.7 (14.7) 61.0 (12.5) 0.79
Median 64.0 63.5 64.0
Range 27–96 27–96 28–82
Hispanic/Latino –
Yes 44 (29.3) 0 (0.0) 44 (100.0)
No 106 (70.7) 106 (100.0) 0 (0.0)
Race
African American/Afro
Caribbean/African/Black
20 (13.3) 13 (12.3) 7 (15.9) 0.63
American Indian/Alaskan
Native
0 (0.0) 0 (0.0) 0 (0.0) –
Asian/Pacific Islander 8 (5.3) 8 (7.5) 0 (0.0) 0.11
White 92 (61.3) 82 (77.4) 10 (22.7) \0.001
Mixed race 25 (16.7) 3 (2.8) 22 (50.0) \0.001
Other 6 (4.0) 1 (0.9) 5 (11.4) 0.009
Education \0.001
No formal education 0 (0.0) 0 (0.0) 0 (0.0)
Grade 1–8 16 (10.7) 3 (2.8) 13 (29.5)
Grade 9–12 34 (22.7) 16 (15.1) 16 (40.9)
Some college 22 (14.7) 14 (13.2) 8 (18.2)
College 32 (21.3) 28 (26.4) 4 (9.1)
Graduate degree 46 (30.7) 45 (42.5) 1 (2.3)
Marital status 0.56
Married/living as married 89 (59.3) 65 (61.3) 24 (54.5)
Single 34 (22.7) 25 (23.6) 9 (20.5)
Divorced/separated 18 (12.0) 11 (10.4) 7 (15.9)
Widowed 9 (6.0) 5 (4.7) 4 (9.1)
Health literacy
How often do you understand
information from your physician
0.49
Never 1 (0.7) 1 (0.9) 0 (0.0)
Almost never 0 (0.0) 0 (0.0) 0 (0.0)
Sometimes 37 (24.7) 24 (22.6) 13 (29.5)
All the time 112 (74.7) 81 (76.4) 31 (70.5)
How often do you need help
with instructions and
information from your physician
or pharmacy
\0.001
Never 77 (51.7) 64 (61.0) 13 (29.5)
Almost never 25 (16.8) 21 (20.0) 4 (9.1)
Sometimes 37 (24.8) 17 (16.2) 20 (45.5)
All the time 10 (6.7) 3 (2.9) 7 (15.9)
Clinical trials knowledge and participation
Know what a clinical trial is \0.001
Yes 110 (73.3) 89 (84.0) 21 (47.7)
No 40 (26.7) 17 (16.0) 23 (52.3)
Ever invited to participate in a
clinical trial
Yes 32 (21.3) 27 (25.5) 5 (11.4) 0.055
No 118 (78.7) 79 (74.5) 39 (88.6)
Join the trial 0.46
Yes 21 (14.0) 17 (63.0) 4 (80.0)
No 11 (7.3) 10 (37.0) 1 (20.0)
(continued)
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p = 0.055). However, when asked if they would partici-
pate in a clinical trial today if asked, 36.4% of Hispanic
patients versus 18.9% non-Hispanic patients responded
they would (p = 0.05) and twice as often responded ‘‘I
definitely would’’ to joining a clinical if they thought
their cancer could be cured with standard treatment but
were offered a new treatment that may or may not bet-
ter (47.7% vs 20.8%, p = 0.002) and if there was an
equal chance of receiving either the standard treatment
or the experimental treatment in a trial (52.3% vs
23.6%, p = 0.003) than non-Hispanic patients.
Few physicians and staff (20.7%) agreed that clinical
trials absolutely provide the best treatment available,
and less than half (43.9%) believed that the benefits of
clinical trial participation outweighed any risks or
harms. However, 57.0% felt that being in a clinical trial
helps a patient be more in control of their disease and
treatment (Table 3). One quarter of physicians and
staff believed that patients enroll in clinical trials as a
last resort. Researchers and staff perceived the most
common reasons for patients to enroll in trials were to
get better treatment (93.9%), to get the newest treat-
ment available (92.2%), and because the patient had
no better options (85.6%). The most frequently cited
reasons for declining a trial perceived by researchers
and staff were concern about randomization or getting
a placebo (70.8%), followed by mistrust of the medical
system, science, or researchers (69.2%).
Comparison of results among physicians, staff, and
patients
Comparison of the perceptions of the physicians and
staff to patient attitudes showed that more often,
Table 2. Continued
Total (N = 150) Non-Hispanic (n = 106) Hispanic (n = 44) p
n (%) n (%) n (%)
Circumstances under which participation would be considered
If you were asked to participate
in a CT today, would you
participate
0.05
Yes, I definitely would 36 (24.0) 20 (18.9) 16 (36.4)
I might, not sure, it depends 97 (64.7) 75 (70.8) 22 (50.0)
No, I definitely would not 17 (11.3) 11 (10.4) 6 (13.6)
If you tried all available standard
treatment but it did not work,
would you consider participating
in a CT for a new treatment
0.56
Yes, I definitely would 99 (66.0) 72 (67.9) 27 (61.4)
I might, not sure, it depends 47 (31.3) 32 (30.2) 15 (34.1)
No, I definitely would not 4 (2.7) 2 (1.9) 2 (4.5)
If you thought your cancer was
incurable, would you consider
participating in a CT for a new
treatment
0.12
Yes, I definitely would 109 (72.7) 78 (73.6) 31 (70.5)
I might, not sure, it depends 35 (23.3) 26 (24.5) 9 (20.5)
No, I definitely would not 6 (4.0) 2 (1.9) 4 (9.1)
If you thought your cancer could
be cured with standard
treatment, would you consider
participating in a CTof a new
treatment that may or may not
be better
0.002
Yes, I definitely would 43 (28.7) 22 (20.8) 21 (47.7)
I might, not sure, it depends 78 (52.0) 64 (60.4) 14 (31.8)
No, I definitely would not 29 (19.3) 20 (18.9) 9 (20.5)
If you were offered participation
in a CT and there was an equal
chance you would either receive
standard treatment or a new
treatment, would you consider
participating in that CT
0.003
Yes, I definitely would 48 (32.0) 25 (23.6) 23 (52.3)
I might, not sure, it depends 85 (56.7) 67 (63.2) 18 (40.9)
No, I definitely would not 17 (11.3) 14 (13.2) 3 (6.8)
SD: standard deviation; CT: clinical trial.
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patients endorsed a positive attitude about trial invol-
vement, differing significantly from the views of the
physicians and staff (Table 3). Patients more often
agreed that the benefits of participation outweigh the
risks or harms (57.0% vs 43.9%, p = 0.03). In addi-
tion, patients also more frequently reported negative
attitudes toward clinical trials, many of which diverged
significantly from the perceptions of physicians and
staff. Patients more often than researchers believed that
clinical trials are only offered to people whose disease
is hopeless (27.3% vs 8.7%, p \ 0.001), that being in a
clinical trial does not help patients personally (32.9%
vs 1.8%, p \ 0.001), that enrolling in a clinical trial is
gambling with their life (20.8% vs 11.3%, p = 0.04),
Table 3. Comparison of clinical trial attitudes and reasons for participation or declination of clinical trial offers as perceived by
physicians and staff and reported by cancer patients.
Physician/staff, N = 120 Patient, N = 150 P value
Clinical trial attitudes
Positive attitudes n (%) n (%)
Being part of a clinical trial helps patients be more in
control of their disease and treatment
65 (57.0) 104 (69.3) 0.04
A clinical trial absolutely provides the best treatment
available
24 (20.7) 90 (60.0) \0.001
The benefits to patients of being in a clinical trial
outweigh any risks or harms
50 (43.9) 85 (57.0) 0.03
Clinical trials are important to the advancement of
medical science and clinical cancer care
115 (99.1) 148 (98.7) 0.72
Negative attitudes
Clinical trials are only offered to people whose
disease is hopeless
10 (8.7) 41 (27.3) \0.001
Being in a clinical trial does not help patients
personally
2 (1.8) 49 (32.9) \0.001
Patients who enroll in a clinical trial are gambling
with their life
13 (11.3) 31 (20.8) 0.04
Doctors only offer clinical trials as a last resort 14 (12.2) 35 (23.5) 0.019
Patients enroll in clinical trials as a last resort 29 (25.4) 36 (24.0) 0.79
Clinical trials are only good for the doctors, not for
the patients
5 (4.3) 20 (13.4) 0.013
Reasons to participate in a clinical trial n = 21
To get better treatment 108 (93.9) 20 (95.2) 1.00
Help people in the future 92 (80.0) 18 (85.7) 0.76
To get newest treatment available 107 (92.2) 19 (90.5) 0.68
Doctor recommended it 100 (84.0) 19 (90.5) 0.74
Family wanted it 56 (50.0) 7 (33.3) 0.07
Wanted a better chance at a cure 94 (80.3) 20 (95.2) 0.12
Had no better options 101 (85.6) 8 (38.1) \0.001
Reasons to decline participation in a clinical trial n = 11
Patient-related factors
Language/cultural barriers 69 (57.5) 3 (27.3) 0.052
Religious reasons 27 (22.5) 0 (0.0) 0.021
Lack of understanding about research trials 76 (63.3) 1 (9.1) 0.001
Lack of interest in clinical trials 41 (34.2) 4 (40.0) 0.71
Psychosocial factors
Mistrust of the medical system/science/researchers 83 (69.2) 4 (36.4) 0.043
Feeling physically or emotionally Overwhelmed 77 (64.2) 2 (18.2) 0.003
Logistic factors
Inconvenience 71 (59.2) 3 (27.3) 0.04
Lack of transportation 54 (45.0) 4 (36.4) 0.75
Family/personal responsibilities 43 (35.8) 2 (18.2) 0.33
Trial-related factors
Invasive procedures 50 (41.7) 1 (9.1) 0.02
Concerns about toxicity 72 (60.0) 2 (18.2) 0.006
Concerns about randomization or getting a placebo 85 (70.8) 3 (27.3) 0.005
Preference for a proven treatment 69 (57.5) 5 (45.5) 0.53
Financial concerns
Lack of insurance coverage 35 (29.2) 1 (9.1) 0.29
Additional out-of-pocket costs 44 (36.7) 2 (18.2) 0.33
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and that clinical trials are offered as a last resort
(23.5% vs 12.2%, p 0.019).
Of patients offered a clinical trial and who agreed to
participate (n = 21), opinions differed from those of
the physicians and staff with 38.1% of patients who
stated that having no better options was a consider-
ation when making their decision to join compared to
85.6% of physicians who believed this was an impor-
tant consideration for patients (p \ 0.001). Among
patients who were offered participation in a clinical
trial but declined (n = 11), most frequent reasons for
this choice were preference for a proven treatment
(45.5%), lack of interest (40.0%). Reasons for declining
participation cited by patients also varied significantly
from those perceived by physicians and staff. For
example, physicians/staff more often believed
that patients decline clinical trial participation because
of language and cultural barriers (57.5% vs 27.3%,
p \ 0.001), lack of understanding about clinical trials
(63.3% vs 9.1%, p = 0.001), and mistrust of the medi-
cal system (69.2% vs 36.4%, p = 0.043) compared to
patient report. Patients also less often reported declin-
ing participation because of invasive procedures (9.1%
vs 41.7%, p = 0.02), concerns about toxicity (18.2%
vs 60.0%, p = 0.006), and reluctance to be randomized
or to receive a placebo (27.3% vs 70.8%, p = 0.005).
Discussion
Our findings demonstrate barriers to trial participation
are frequent at the structural, provider, and patient lev-
els. In addition, we found significant differences in per-
ceived patient barriers to trial enrollment between
research physicians and their staff; differences in bar-
riers, attitudes, and beliefs between Hispanic and non-
Hispanic patients; and, most importantly, differences
between what research physicians and staff believe are
barriers for patients and what patients report as
barriers.
The process of enrolling a cancer patient onto a clin-
ical trial is multifaceted with the potential for break-
down at several key junctures along the way. Typically,
patients newly diagnosed with cancer visit a cancer
clinic and, depending on site infrastructure and proto-
cols, are evaluated for trial eligibility. Assessment of
eligibility, however, is contingent upon the availability
of trials for the particular histology or stage of a
patient’s cancer.3 In a recent systematic review and
meta-analysis of multi-level clinical trials barriers,
Unger et al. reported that structural barriers are per-
haps the greatest of barriers to trial participation; clini-
cal trials were not available for 55.6% of cancer
patients, and another 2.15% were ineligible for trials
that were available.3 The structural barriers identified
in our study that included difficulty in keeping track of
eligibility criteria and carving out time during a visit to
discuss trials and enrollment further complicate the
first crucial step in the process of enrolling patients to
clinical trials.
Once assessed as eligible for an available trial, the
physician may or may not choose to discuss and offer
trial enrollment to the patient. Physician bias and its
impact on the decision whether or not offer a given
patient a clinical trial has not been fully investigated.
One example is a study conducted by Kornblith et al.
that examined physician perceptions of barriers to clini-
cal trials among elderly breast cancer patients.
Physicians reported reluctance to enroll elderly patients
due to comorbid conditions not excluded by trial pro-
tocol; that elderly patients would not fully understand
trial procedures and would therefore likely be non-
compliant; and that older patients may experience
greater toxicity.31 Others have similarly reported how
conscious and unconscious implicit physician bias
against a patient’s age and comorbidities as well as bias
against members of minority groups and perceptions of
patient mistrust of researchers.17 These biases some-
times result in spontaneous and reflexive decisions
about the candidacy of a patient for a trial, influence
patient–provider interactions, and lead to foregoing
clinical trial options during discussions about treatment
thus limiting offers of enrollment.17,32,33 Physician bias
may also contribute to poor accrual to trials and early
trial closure in addition to the lost opportunity to pro-
vide new treatments and better ancillary patient
care.3,17
Only at the end of this process of negotiating struc-
tural and provider-level barriers does the patient’s deci-
sion to participate enter the equation. Patients in our
study more frequently endorsed negative attitudes
about clinical trials, such as only being offered to those
whose disease is hopeless, not helping patients person-
ally, participation is gambling with one’s life, and only
being good for the doctor, not the patient. Consistent
with prior literature, a significant number of patients
cited a preference for standard treatment or a lack of
interest in participating in clinical research as a reason
for declining.34 Furthermore, our results demonstrate a
significant difference in clinical trial knowledge and
attitudes by ethnicity, with Hispanics reporting less
awareness about clinical trials which is consistent with
previously literature reporting lower participation in
clinical trials in racial and ethnic minority groups.13
We also found that, despite less awareness of clinical
trials and greater reported negative attitudes toward
trials, Hispanic patients were more willing to consider a
trial than their non-Hispanic counterparts were. When
posed hypothetical conditions under which a patient
might consider clinical trial participation, only a small
proportion of patients overall stated that they definitely
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would not participate with Hispanics twice as often
stating they would definitely participate. These findings
are aligned with those of Comis et al. who reported
that most Americans hold favorable views of clinical
trial participation.19
Discordance between what physicians and research
staff perceive as barriers and what patients state has
not been previously reported. In our study, physicians
and research staff often over- and under-estimated the
importance of patient-reported barriers and highlight
the ongoing communication that is needed between the
provider/staff and patient. A study by Albrecht et al. of
videotaped outpatient interactions between oncologists
and patients and their family, when present, at two
comprehensive cancer centers found that clinical trial
participation was only offered to 20% of participants
previously determined to be eligible for a trial, but
when offered, 75% of these eligible patients assented.
Greater shared conversation control with the physician
was significantly related to the patient’s decision to
enroll highlighting the importance of content and rela-
tional communication between physicians and patients,
provider–patient alliance building, and supportive dia-
logue in a full, clear, and open discussion of clinical
trial participation.35
Our study had some strengths worth highlighting.
First, we developed the survey from key informant
interviews which revealed key structural and provider-
related topics that we included in our quantitative sur-
vey. This participatory research process ensured that
we were asking relevant questions related to the topic.
However, we did not include a patient representative in
the development of our survey; this would have
strengthened our study further. This is a single site,
observational study conducted at a large urban
Minority-Underserved NCORP site within an NCI-
designated comprehensive cancer center in New York
City, which may limit generalizability of our findings to
other geographic areas and patient populations. A
major strength of this study is the unique assessment of
the knowledge, attitudes, and beliefs of physicians and
staff in parallel with those of patients. This allows us to
have greater insight into the individual groups, but also
to better develop tailored interventions within appro-
priate groups. Tailored, multi-level interventions have
been cited as the most successful to reduce barriers to
CTE, and the level of granularity and comparison that
our data provides will support future initiatives.
Conclusion
Our study highlights the knowledge, attitudes, and
beliefs about CTE from provider, staff, and patient per-
spectives and support previously defined barriers to
clinical trial participation, specifically between Hispanic
and non-Hispanic groups. These data also provide new
information about the gaps between provider-/staff-
and patient-perceived barriers. Specifically, to our
knowledge, this is the first published comprehensive
assessment across physicians, staff, and patients to
understand differences in perceptions about CTE bar-
riers. Attitudes can be defined as a ‘‘learned tendency to
evaluate things in a certain way’’ that are informed by
personal experience, social norms, conditioning, and
observation.36 Differences in attitudes between provi-
ders and patients are important to understand in order
to focus future initiatives to raise awareness about
incongruency between each group and reduce implicit
biases. One possible strategy to address discordant pro-
vider/patient attitudes could be to incorporate these
same factors that lead to the development of attitudes
into educational interventions to effect attitude change.
For example, enhancing personal CTE experiences for
patients and providers through improved communica-
tion and streamlined workflow or promoting the enroll-
ment of racial and ethnic minorities onto clinical trials
as an institution-wide desired social norm. Clear, trans-
parent communication between providers, staff, and
patients about clinical trials should also be emphasized,
as this will help to reduce inconsistencies across provi-
der/patient continuum and in addition, help to reduce
medical mistrust.22 Other strategies such as educating
patients about clinical trials prior to their first oncology
visit,37 engaging the community, diversifying the clinical
and research staff to be more representative of the
community, and providing education to the commu-
nity and providers/staff may also help to reduce these
barriers.22
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